PMID- 35111147
OWN - NLM
STAT- MEDLINE
DCOM- 20220223
LR  - 20231213
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 12
DP  - 2021
TI  - Influence of T Cell-Mediated Immune Surveillance on Somatic Mutation Occurrences 
      in Melanoma.
PG  - 703821
LID - 10.3389/fimmu.2021.703821 [doi]
LID - 703821
AB  - BACKGROUND: Neoantigens are presented on the cancer cell surface by 
      peptide-restricted human leukocyte antigen (HLA) proteins and can subsequently 
      activate cognate T cells. It has been hypothesized that the observed somatic 
      mutations in tumors are shaped by immunosurveillance. METHODS: We investigated 
      all somatic mutations identified in The Cancer Genome Atlas (TCGA) Skin Cutaneous 
      Melanoma (SKCM) samples. By applying a computational algorithm, we calculated the 
      binding affinity of the resulting neo-peptides and their corresponding wild-type 
      peptides with the major histocompatibility complex (MHC) Class I complex. We then 
      examined the relationship between binding affinity alterations and mutation 
      frequency. RESULTS: Our results show that neoantigens derived from recurrent 
      mutations tend to have lower binding affinities with the MHC Class I complex 
      compared to peptides from non-recurrent mutations. Tumor samples harboring 
      recurrent SKCM mutations exhibited lower immune infiltration levels, indicating a 
      relatively colder immune microenvironment. CONCLUSIONS: These results suggested 
      that the occurrences of somatic mutations in melanoma have been shaped by 
      immunosurveillance. Mutations that lead to neoantigens with high MHC class I 
      binding affinity are more likely to be eliminated and thus are less likely to be 
      present in tumors.
CI  - Copyright (c) 2022 Jiang, Schaafsma, Hong, Zhao, Zhu, Chao and Cheng.
FAU - Jiang, Chongming
AU  - Jiang C
AD  - Department of Medicine, Baylor College of Medicine, Houston, TX, United States.
FAU - Schaafsma, Evelien
AU  - Schaafsma E
AD  - Department of Molecular and Systems Biology, Dartmouth College, Hanover, NH, 
      United States.
FAU - Hong, Wei
AU  - Hong W
AD  - Department of Medicine, Baylor College of Medicine, Houston, TX, United States.
FAU - Zhao, Yanding
AU  - Zhao Y
AD  - Department of Medicine, Baylor College of Medicine, Houston, TX, United States.
FAU - Zhu, Ken
AU  - Zhu K
AD  - Medical School, UT Southwestern Medical Center, Dallas, TX, United States.
FAU - Chao, Cheng-Chi
AU  - Chao CC
AD  - Antibody Discovery, Chempartner Corporation, South San Francisco, CA, United 
      States.
FAU - Cheng, Chao
AU  - Cheng C
AD  - Department of Medicine, Baylor College of Medicine, Houston, TX, United States.
AD  - Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, 
      TX, United States.
AD  - Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, 
      Lebanon, NH, United States.
AD  - The Institute for Clinical and Translational Research, Baylor College of 
      Medicine, Houston, TX, United States.
LA  - eng
GR  - R21 CA227996/CA/NCI NIH HHS/United States
GR  - T32 AI007363/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20220117
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Peptides)
SB  - IM
MH  - Antigens, Neoplasm/immunology
MH  - Histocompatibility Antigens Class I/immunology
MH  - Humans
MH  - Immunologic Surveillance/*immunology
MH  - Immunotherapy/methods
MH  - Melanoma/*immunology
MH  - Mutation/*immunology
MH  - Mutation Rate
MH  - Peptides/immunology
MH  - Skin Neoplasms/*immunology
MH  - T-Lymphocytes/*immunology
MH  - Tumor Microenvironment/immunology
MH  - Melanoma, Cutaneous Malignant
PMC - PMC8801458
OTO - NOTNLM
OT  - Melanoma
OT  - antigen presentation
OT  - immunosurveillance
OT  - neoantigen
OT  - recurrent mutation
COIS- Author C-CC was employed by the company Chempartner Corporation. The remaining 
      authors declare that the research was conducted in the absence of any commercial 
      or financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2022/02/04 06:00
MHDA- 2022/02/24 06:00
PMCR- 2021/01/01
CRDT- 2022/02/03 05:33
PHST- 2021/04/30 00:00 [received]
PHST- 2021/12/16 00:00 [accepted]
PHST- 2022/02/03 05:33 [entrez]
PHST- 2022/02/04 06:00 [pubmed]
PHST- 2022/02/24 06:00 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2021.703821 [doi]
PST - epublish
SO  - Front Immunol. 2022 Jan 17;12:703821. doi: 10.3389/fimmu.2021.703821. eCollection 
      2021.